CN115501184B - 基于peg-plga聚合物胶束的重症哮喘治疗用探针 - Google Patents
基于peg-plga聚合物胶束的重症哮喘治疗用探针 Download PDFInfo
- Publication number
- CN115501184B CN115501184B CN202211382766.1A CN202211382766A CN115501184B CN 115501184 B CN115501184 B CN 115501184B CN 202211382766 A CN202211382766 A CN 202211382766A CN 115501184 B CN115501184 B CN 115501184B
- Authority
- CN
- China
- Prior art keywords
- polymer micelle
- peg
- severe asthma
- therapeutic agent
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000693 micelle Substances 0.000 title claims abstract description 43
- 229920000642 polymer Polymers 0.000 title claims abstract description 34
- 208000006673 asthma Diseases 0.000 title claims abstract description 25
- 239000000523 sample Substances 0.000 title claims abstract description 22
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 16
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 9
- 229960004017 salmeterol Drugs 0.000 claims abstract description 9
- 239000000975 dye Substances 0.000 claims abstract description 5
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 10
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 10
- 239000002086 nanomaterial Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 5
- 239000000443 aerosol Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明的基于PEG‑PLGA聚合物胶束的重症哮喘治疗用探针，属于哮喘治疗技术领域，包括聚合物胶束和治疗剂，治疗剂表面包覆聚合胶束，治疗剂包括近红外光染料IR780荧光探针和沙美特罗，采用雾化吸入的方式进入肺部，治疗的疾病为重症哮喘，可以直接到达病灶，治疗效果好，提高利用率。
Description
技术领域
本发明属于重症哮喘治疗技术领域，更具体来说，涉及一种基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针。
背景技术
支气管哮喘(bronchial asthma)是由多种细胞(如嗜酸性粒细胞、肥大细胞、T淋巴细胞、中性粒细胞、气道上皮细胞等)和细胞组分参与的气道慢性炎症为特征的异质性疾病，这种慢性炎症与气道高反应性相关，通常出现广泛而多变的可逆性呼气气流受限，导致反复发作的喘息、气促、胸闷和(或)咳嗽等症状，强度随时间变化。多在夜间和(或)清晨发作、加剧，多数患者可自行缓解或经治疗缓解。支气管哮喘如诊治不及时，随病程的延长可产生气道不可逆性缩窄和气道重塑。
发明内容
1.发明要解决的技术问题
本发明的目的在于解决现有重症哮喘的治疗问题。
2.技术方案
为达到上述目的，本发明提供的技术方案为：
本发明的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，包括聚合物胶束和治疗剂，治疗剂表面包覆聚合胶束，治疗剂包括近红外光染料IR780荧光探针和沙美特罗。
优选的，聚合物胶束基于PEG-PLGA，聚合物胶束表面带有Siglec-9抗体。
优选的，聚合物胶束具有油溶性。
优选的，聚合物胶束为纳米结构。
优选的，Siglec-9抗体均匀分布在聚合物胶束的表面。
3.有益效果
采用本发明提供的技术方案，与现有技术相比，具有如下有益效果：
(1)本发明的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，包括聚合物胶束和治疗剂，治疗剂表面包覆聚合胶束，治疗剂包括近红外光染料IR780荧光探针和沙美特罗，采用雾化吸入的方式进入肺部，治疗的疾病为重症哮喘，可以直接到达病灶，治疗效果好，提高利用率。
附图说明
图1为本发明的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针的结构示意图；
图2为本发明的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针的治疗流程示意图。
示意图中的标号说明：
100、聚合物胶束；
200、IR780荧光探针
300、沙美特罗；
400、Siglec-9抗体。
具体实施方式
为了便于理解本发明，下面将参照相关附图对本发明进行更全面的描述，附图中给出了本发明的若干实施例，但是，本发明可以以许多不同的形式来实现，并不限于本文所描述的实施例，相反地，提供这些实施例的目的是使对本发明的公开内容更加透彻全面。
需要说明的是，当元件被称为“固设于”另一个元件，它可以直接在另一个元件上或者也可以存在居中的元件；当一个元件被认为是“连接”另一个元件，它可以是直接连接到另一个元件或者可能同时存在居中元件；本文所使用的术语“垂直的”、“水平的”、“左”、“右”以及类似的表述只是为了说明的目的。
除非另有定义，本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同；本文中在本发明的说明书中所使用的术语只是为了描述具体的实施例的目的，不是旨在于限制本发明；本文所使用的术语“及/或”包括一个或多个相关的所列项目的任意的和所有的组合。
实施例1
参照附图1-图2所示，本实施例的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，包括聚合物胶束100和治疗剂，治疗剂表面包覆聚合胶束100，治疗剂包括近红外光染料IR780荧光探针200和沙美特罗300，采用雾化吸入的方式进入肺部，治疗的疾病为重症哮喘，可以直接到达病灶，治疗效果好，提高利用率。
本实施例的聚合物胶束100基于PEG-PLGA，聚合物胶束100表面带有Siglec-9抗体400。
本实施例的聚合物胶束100具有油溶性。
本实施例的聚合物胶束100为纳米结构。
本实施例的Siglec-9抗体400均匀分布在聚合物胶束100的表面。
PLGA-PEG的聚合物胶束100表面带有羧基可以修饰Siglec-9抗体400，帮助纳米粒子靶向到重症哮喘病灶区域起到靶向治疗的作用。
该纳米探针采用雾化吸入的方式进入肺部，治疗的疾病为重症哮喘，可以直接到达病灶，沙美特罗300和Siglec-9抗体400都能起到治疗作用，IR780荧光探针200可以起到指示剂的作用，证明纳米探针到达肺部。
1、载IR780荧光探针的PLGA-PEG-COOH胶囊制备(50mg)
取500μL PLGA10K-mPEG5K(100mg/mL)，50μL IR780(10mg/mL)，450μL三氯甲烷混合均匀，加入到6mL 1％的PVA和TPGS的混合液(外水相，PVA：TPGS为1：5)中，在冰浴情况下用探头超声超声5分钟(80W)形成油-水复乳。最后将混合液加入到30mL 0.3％的PVA中(分散相)，搅拌过夜，使氯仿挥发，使PLGA球表面固化。以100KD的超滤管进行超滤浓缩清洗，最后用纯水定容至5mL，将样品收集于4度保存。取适量样本烘干称重计算浓度及固含量。
2、载沙美特罗及IR780荧光探针的PLGA-PEG-COOH胶囊制备(50mg)
取500μL PLGA10K-mPEG5K(100mg/mL)，50μL IR780(10mg/mL)，100μL沙美特罗(20mg/mL)，350μL三氯甲烷混合均匀，加入到6mL 1％的PVA和TPGS的混合液(外水相，PVA：TPGS为1：5)中，在冰浴情况下用探头超声超声5分钟(80W)形成油-水复乳。最后将混合液加入到30mL 0.3％的PVA中(分散相)，搅拌过夜，使氯仿挥发，使PLGA球表面固化。以100KD的超滤管进行超滤浓缩清洗，最后用纯水定容至5mL，将样品收集于4度保存。取适量样本烘干称重计算浓度及固含量。
3、载药PLGA-PEG-COOH胶束偶联Siglec-9抗体
取1mL载药PLGA-PEG-COOH胶束(10mg/mL)离心后，更换溶液，分散于0.5mL MES中(100mM，pH 4.8)，加入抗体(300μg)于37℃吸附1h。称取EDC用100mM MES配成240mg/mL溶液，加入80μL，37℃偶联过夜，离心用纯水纯化，最后保存在水中。
以上所述实施例仅表达了本发明的某种实施方式，其描述较为具体和详细，但并不能因此而理解为对本发明专利范围的限制；应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围；因此，本发明专利的保护范围应以所附权利要求为准。
Claims (5)
1.基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，其特征在于：包括聚合物胶束(100)和治疗剂，所述治疗剂表面包覆聚合胶束(100)，所述治疗剂包括近红外光染料IR780荧光探针(200)和沙美特罗(300)。
2.根据权利要求1所述的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，其特征在于：所述聚合物胶束(100)基于PEG-PLGA，所述聚合物胶束(100)表面带有Siglec-9抗体(400)。
3.根据权利要求1所述的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，其特征在于：所述聚合物胶束(100)具有油溶性。
4.根据权利要求1所述的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，其特征在于：所述聚合物胶束(100)为纳米结构。
5.根据权利要求1所述的基于PEG-PLGA聚合物胶束的重症哮喘治疗用探针，其特征在于：所述Siglec-9抗体(400)均匀分布在聚合物胶束(100)的表面。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211382766.1A CN115501184B (zh) | 2022-11-07 | 2022-11-07 | 基于peg-plga聚合物胶束的重症哮喘治疗用探针 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211382766.1A CN115501184B (zh) | 2022-11-07 | 2022-11-07 | 基于peg-plga聚合物胶束的重症哮喘治疗用探针 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115501184A CN115501184A (zh) | 2022-12-23 |
| CN115501184B true CN115501184B (zh) | 2023-08-08 |
Family
ID=84512085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211382766.1A Active CN115501184B (zh) | 2022-11-07 | 2022-11-07 | 基于peg-plga聚合物胶束的重症哮喘治疗用探针 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115501184B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106699845A (zh) * | 2015-11-12 | 2017-05-24 | 复旦大学 | stapled-RGD多肽及其在肿瘤靶向递送中的应用 |
| CN109985006A (zh) * | 2017-12-29 | 2019-07-09 | 复旦大学 | 一种光热辅助穿透的诊疗型纳米药物 |
| CN110787306A (zh) * | 2018-08-02 | 2020-02-14 | 武汉凯德维斯生物技术有限公司 | 一种用于宫颈癌前哨淋巴结的纳米胶束显像剂的制备与应用 |
| CN115154419A (zh) * | 2021-04-02 | 2022-10-11 | 中国科学院上海药物研究所 | 一种纳米胶束前体和纳米胶束，其制备方法及应用 |
-
2022
- 2022-11-07 CN CN202211382766.1A patent/CN115501184B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106699845A (zh) * | 2015-11-12 | 2017-05-24 | 复旦大学 | stapled-RGD多肽及其在肿瘤靶向递送中的应用 |
| CN109985006A (zh) * | 2017-12-29 | 2019-07-09 | 复旦大学 | 一种光热辅助穿透的诊疗型纳米药物 |
| CN110787306A (zh) * | 2018-08-02 | 2020-02-14 | 武汉凯德维斯生物技术有限公司 | 一种用于宫颈癌前哨淋巴结的纳米胶束显像剂的制备与应用 |
| CN115154419A (zh) * | 2021-04-02 | 2022-10-11 | 中国科学院上海药物研究所 | 一种纳米胶束前体和纳米胶束，其制备方法及应用 |
Non-Patent Citations (1)
| Title |
|---|
| Kemal.E,et al.Bright, near infrared emitting PLGA–PEG dyedoped CN-PPV nanoparticles for imaging applications.RSC Advances.2017,第7卷15255–15264. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115501184A (zh) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wen et al. | Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration | |
| WO2018041261A1 (zh) | 一种肿瘤治疗药物 | |
| JP2002506436A (ja) | 治療用ナノスフェア | |
| WO2021027425A1 (zh) | 一种抗炎靶向递送系统及其制备方法 | |
| CN113398283B (zh) | 一种基于生物膜耦合的可吸入雾化微球及制备方法与应用 | |
| CN104338152A (zh) | 医用靶向造影剂微球 | |
| CN102357079A (zh) | 一种甘草酸修饰羧甲基壳聚糖纳米粒及其制备方法和应用 | |
| Li et al. | Platelet compatibility of PLGA, chitosan and PLGA–chitosan nanoparticles | |
| CN105030692B (zh) | 一种硫酸头孢喹诺的肺靶向plga微球制剂及其制备方法 | |
| CN104288093B (zh) | 纳米药物透皮制剂在肿瘤中的应用 | |
| CN115501184B (zh) | 基于peg-plga聚合物胶束的重症哮喘治疗用探针 | |
| Zhang et al. | The protective effect of puerarin-loaded mesoporous silicon nanoparticles on alcoholic hepatitis through mTOR-mediated autophagy pathway | |
| CN109125741A (zh) | 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法 | |
| Liu et al. | Targeted Delivery of Macrophage Membrane Biomimetic Liposomes Through Intranasal Administration for Treatment of Ischemic Stroke | |
| CN114939165B (zh) | 可逆转多药耐药性的双金属纳米粒及其制备方法和应用 | |
| CN106265607A (zh) | 一种用于肺吸入壳聚糖基纳米靶向聚合粒子及其制备方法 | |
| CN113797226B (zh) | 氨硼烷/硅球/介孔二氧化硅纳米复合粒子及其制备与应用 | |
| Ye et al. | Comparative colloidal stability of commercial amphotericin b nanoformulations using dynamic and static multiple light scattering techniques | |
| CN109999009B (zh) | 一种抗肿瘤药物口服缓释制剂及其制备方法 | |
| Wang et al. | Biomimetic Integrated Nanozyme for Flare and Recurrence of Gouty Arthritis | |
| Chen et al. | Cholesterol-linoleic acid liposomes induced extracellular vesicles secretion from immortalized adipose-derived mesenchymal stem cells for in vitro cell migration | |
| CN113797177B (zh) | 一种离子乳化剂壳聚糖纳米粒修饰的槲皮素口服缓释制剂及其制备方法 | |
| He et al. | Evaluation of the efficacy and performance of a new nano-drug carrier in the treatment of recurrent oral ulcerper | |
| CN104436228A (zh) | 新型磁性三氧化二铁中空微球造影剂 | |
| Modrzynska | Toxicological effects of nanoparticle deposition in the liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230918 Address after: 300 Guangzhou road, Nanjing, Jiangsu Province 210000 Patentee after: JIANGSU PROVINCE HOSPITAL(The First Affiliated Hospital of Nanjing Medical University) Patentee after: Xuzhou Zhunhai Life Science Industry Research Institute Co.,Ltd. Address before: 221116 Workshop A5, No. 10, Zhujiang East Road, No. 3 Industrial Park, High tech Industrial Development Zone, Xuzhou City, Jiangsu Province Patentee before: Xuzhou Huaihai Life Science Industry Research Institute Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CI03 | Correction of invention patent |
Correction item: Patentee|Address|Patentee Correct: Xuzhou Huaihai Life Science Industry Research Institute Co.,Ltd.|221116 Workshop A5, No. 10, Zhujiang East Road, No. 3 Industrial Park, High tech Industrial Development Zone, Xuzhou City, Jiangsu Province False: JIANGSU PROVINCE HOSPITAL(The First Affiliated Hospital of Nanjing Medical University)|300 Guangzhou road, Nanjing, Jiangsu Province 210000|Xuzhou Zhunhai Life Science Industry Research Institute Co.,Ltd. Number: 41-01 Volume: 39 |
|
| CI03 | Correction of invention patent | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231212 Address after: 300 Guangzhou road, Nanjing, Jiangsu Province 210000 Patentee after: JIANGSU PROVINCE HOSPITAL(The First Affiliated Hospital of Nanjing Medical University) Patentee after: Xuzhou Huaihai Life Science Industry Research Institute Co.,Ltd. Address before: 221116 Workshop A5, No. 10, Zhujiang East Road, No. 3 Industrial Park, High tech Industrial Development Zone, Xuzhou City, Jiangsu Province Patentee before: Xuzhou Huaihai Life Science Industry Research Institute Co.,Ltd. |
|
| TR01 | Transfer of patent right |